statistics
 
Home   Contact Us   Sitemap



 Financials  Annual Reports/Postal Ballot  Presentations  Analysts Reports  Evoting/Poll Results
 Stock Price  Message From the Top Management  Shareholding Pattern  Corporate Policies  Investor Grievances
 Unpaid Dividend  Subsidiaries Annual Report  
 
 

 
 
Press Releases :
 

Indoco's Net Revenues Up by 16% Q-o-Q
Receives ANDA approval for Allopurinol tablets

July 29, 2016
Indoco Remedies Q4 net profit rises 6.7% to 20 crore aided by exports
May 27, 2016
Indoco Remedies Q3 sales rises 19.6% as domestic business bounces back
January 29, 2016
Indoco Remedies Q2 Net Revenues rise 9% Y-o-Y to 248 crores
October 30, 2015
Indoco Remedies Q1FY16 PAT grows QoQ at 8% to Rs. 20.3 Crores
July 30, 2015
Net Revenues of Indoco Remedies rise by 14% at Rs.212 Crores
May 27, 2015
Indoco Remedies Q3 Profit After Tax (PAT) grows by 53%
January 30, 2015
Indoco Remedies Q2 Profit After Tax (PAT) grows by 40%
October 21, 2014
Indoco Remedies Q1 Net Profit up 118%
July 30, 2014
Indoco's Profit Grows by 44%
May 28, 2014
Indoco’s Profit Doubles on Higher Sales
January 29, 2014
Indoco's Sales and EBIDTA margins improve substantially
October 30, 2013
Indoco maintains performance amidst adverse business conditions
July 30, 2013
Indoco’s Revenues grows by 11.8% Y-o-Y
May 28, 2013
Indoco’s domestic business outperforms the industry growth rates
January 29, 2013
Indoco's Revenues Grows by 13.5%
November 2, 2012
Indoco’s Revenues Grow by 20.2% with improved EBIDTA margins
July 30, 2012
Indoco’s Revenues Grow by 22.4% Q-o-Q and by 16.9% Y-o-Y
May 28, 2012
Indoco’s Revenues Grow by 24 %
February 14, 2012
Indoco’s Revenues Grow by 9 %
October 20, 2011
Indoco’s Revenues Grow by 13 %
July 28, 2011
Indoco’s Profit After Tax Grows by 48 %
April 27, 2011
Indoco’s Revenues Grows By 20%
Profit Before Tax Grows By 35%
January 20, 2011
 
 
Indoco's Profit Grows by 44%
May 28, 2014

May 28, 2014, Mumbai: Indoco Remedies Limited has recorded a total revenue growth of 15.8 % at Rs. 185.9 crores during the fourth quarter of FY 2013-14 as against Rs. 160.5 crores during the same period last year. For the year 2013-14, the net revenues grew by 14.5% at Rs. 717.4 Crs as against Rs. 626.4 Crs. EBIDTA to net sales for the quarter is 19.9 % at Rs. 37.0 Crs as against 17.4 % at Rs. 27.9 Crs during the same quarter last year and for the year, it is 18.7 % at Rs. 134.5 Crs as against 16.8 % at Rs. 105.4 Crs last year. Profit before tax (PBT) to net sales for the quarter is 12.1 % at Rs. 22.6 Crs as against 8.9% at Rs. 14.3 Crs during the same quarter last year. For the year, PBT is 10.1% at Rs. 72.1 Crs as against 7.7 % at Rs. 48.4 Crs last year..

Profit after tax (PAT) grew by 44.4% for the quarter and is 10.0 % of net sales at Rs. 18.5 Crs as against 8.0% at Rs. 12.8 Crs during the same quarter last year. For the year, PAT is 8.1% at Rs. 57.9 Crs as against 6.8 % at Rs. 42.7 Crs last year. The un-audited standalone results for the fourth quarter of the FY 2013-14 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on May 28, 2014.

Commenting on the performance, Mr. Suresh G. Kare, Chairman said, "During the quarter, both Domestic as well as International Business segments of Indoco have registered good growth of 13.9% and 18.2% respectively. In the quarter, the Company received approval for its Goa sterile ophthalmic facility from EU Regulatory and also received the 'Best Patent Award 2012-2013' for two of its API process patents at the 52nd IDMA awards. These developments and our belief in our strategies, give us the confidence that the Company is moving faster in the right direction to meet its set goals".

HIGHLIGHTS:

For Fourth Quarter ended 31st March 2014 of FY 2013-14

Net Revenues at Rs. 185.9 crores
EBIDTA at Rs. 37.0 crores
Profit Before Tax at Rs. 22.6 crores
Profit After Tax at Rs. 18.5 crores
EPS at Rs. 2.01


For the Year ended 31st March 2014 of FY 2013-14

Net Revenues at Rs. 717.4 crores
EBIDTA at Rs. 134.5 crores
Profit Before Tax at Rs. 72.1 crores
Profit After Tax at Rs. 57.9 crores
EPS at Rs. 6.28


^Top
 
 
Indoco’s Profit Doubles on Higher Sales
January 29, 2014

January 29, 2014, Mumbai: Indoco Remedies Limited has recorded a total revenue growth of 25.4 % at Rs. 188.4 crores during the third quarter of FY 2013-14 as against Rs. 150.3 crores during the same period last year. EBIDTA as a percentage to net sales for the quarter is 17.8% at Rs. 33.5 crores and the EBIDTA for year to date is 18.3% at Rs. 97.5 crores. Profit after tax as a percentage to net sales for the quarter is 7.5% at Rs. 14.1 crores as against 4.9 % at Rs. 7.4 crores for the same period last year. Profit after tax as a percentage to net sales for the year to date is 7.4% at Rs. 39.3 crores as against 6.4% at Rs. 29.8 crores for the same period last year. The un-audited standalone results for the third quarter of the FY 2013-14 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on January, 29 2014.

Commenting on the performance, Mr. Suresh G. Kare, Chairman said, "Our well formulated strategy and investments made over the years have started giving expected returns, as is obvious from the impressive results for the consecutive quarters. The Company is clearly on fast track with both domestic and international businesses registering a good growth in this quarter. Our Domestic Formulation business growth has surpassed the industry average, and our research pipeline ensures consistent growth of the International Business which is spread across the globe".

HIGHLIGHTS:

For Third Quarter ended 31st December 2013 of FY 2013-14

Net Revenues at Rs. 188.4 crores
EBIDTA at Rs. 33.5 crores
Profit Before Tax at Rs. 18.1 crores
Profit After Tax at Rs. 14.1 crores
EPS at Rs. 1.53


For Nine Months ended 31st December 2013 of FY 2013-14

Net Revenues at Rs. 531.5 crores
EBIDTA at Rs. 97.5 crores
Profit Before Tax at Rs. 49.5 crores
Profit After Tax at Rs. 39.3 crores
EPS at Rs. 4.27


^Top
 
 
Indoco's Sales and EBIDTA margins improve substantially
October 30, 2013

October 30, 2013, Mumbai: Indoco Remedies Limited, recorded total revenue growth of 24.8 % at Rs. 2023.0 million during the second quarter of FY 2013-14 as against Rs. 1620.7 million during the same period last year. The company witnessed significant improvement in EBIDTA margins in this quarter. EBIDTA as a percentage to net sales is 18.9% at Rs. 368.5 million as against 15.9% at Rs. 261.3 million during the same period last year. Profit after tax is Rs. 160.4 million as against Rs. 120.8 million for the same period last year.

The un-audited results for the second quarter of the financial year 2013-14 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on October 30, 2013.

Commenting on the performance, Mr. Suresh G. Kare, Chairman said, "The performance of our company across all segments has been good in the second quarter as seen from the improvement in top line as well as EBIDTA margins. With expected sales growth from Regulated markets and resolution of issues related to implementation of new pricing policy in Domestic markets, we are confident of maintaining the growth momentum in the coming quarters too".

HIGHLIGHTS:

Second Quarter ended September 2013 of FY 2013-14

Net Revenues at Rs. 1950.5 million
EBIDTA at Rs. 368.5 million
Profit After Tax at Rs. 160.4 million
EPS at Rs. 1.74
(Face value of Rs. 2/- per share)


^Top
 
 
Indoco maintains performance amidst adverse business conditions
July 30, 2013

July 30, 2013, Mumbai: Indoco Remedies Limited, a pharmaceutical Company with global presence, recorded revenues at Rs.1480.5 million during the first quarter of FY 2013-14 as compared to Rs. 1511.6 million over the same quarter last year. The un-audited results for the first quarter of the financial year 2013-14 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on July 30, 2013.

Commenting on the performance, Mr. Suresh G. Kare, Chairman said, "Slowdown in the domestic market and pre implementation pangs of pricing policy had an overall impact on our sales. With announcement of the new pricing policy and onset of monsoon, the growth momentum is expected to pick up in the coming quarters. International business revenue & margins will improve with the commencement and ramp up of sales of sterile formulations in US markets and take the company on high growth trajectory."

HIGHLIGHTS:

First Quarter ended June 2013 of FY 2013-14

Net Revenues at Rs. 1480.5 million
Profit Before Tax at Rs. 110.0 million
Profit After Tax at Rs. 91.8 million
EPS at Rs. 1.0
(Face value of Rs. 2/- per share after split & bonus)


^Top
 
 
Indoco’s Revenues grows by 11.8% Y-o-Y
May 28, 2013

May 28, 2013, Mumbai: Indoco Remedies Limited, a pharmaceutical Company with global presence, recorded revenues at Rs. 1604.8 million during the fourth quarter of FY 2012-13 as compared to Rs. 1476.6 million over the same quarter last year. The un-audited results for the fourth quarter of the financial year 2012-13 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on May 28, 2013.

Commenting on the performance, Mr. Suresh G. Kare, Executive Chairman said, "I am glad that the domestic formulation sales in the fourth quarter surpassed the industry average growth rate. The much awaited Drug Pricing Policy has now been announced and the impact on the Company is marginal. The business from USA is expected to ramp up with a few ANDAs slated for approval thereby giving boost to the International Business revenues. Going forward, the Company will accelerate sales growth with improved margins."

HIGHLIGHTS:

Fourth Quarter ended March 2013 of FY 2012-13

Net Revenues at Rs. 1604.8 million
EBIDTA at Rs. 282.2 million
Profit After Tax at Rs. 128.5 million
EPS at Rs. 1.39
(Face value of Rs. 2/- per share after split & bonus)


Year ended March 2013 of FY 2012-13

Net Revenues at Rs. 6264.3 million
EBIDTA at Rs. 1059.8 million
Profit After Tax at Rs. 426.6 million
EPS at Rs. 4.63
(Face value of Rs. 2/- per share after split & bonus)

The consolidated EBIDTA for the year stood at Rs. 1061.6 million, operating profit at Rs. 605.6 million and Profit After Tax (PAT) at Rs. 427.2 million.

^Top
 
 
Indoco’s domestic business outperforms the industry growth rates
January 29, 2013

January 29, 2013, Mumbai: Indoco Remedies Limited, a pharmaceutical company with global presence, recorded revenues at OB9 1502.6 million during the third quarter of FY 2012-13 as compared to Rs.1417.5 million over the same quarter last year. Company’s Domestic formulation business registered a growth of 11% as against Indian Pharma Market (IPM) growth of 9.1% during the quarter. The un-audited results for the third quarter of the financial year 2012-13 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on January 29, 2013.

Commenting on the performance, Mr. Suresh G. Kare, Executive Chairman said, "The Indian Pharma Market witnessed some slow down during the last quarter but is expected to rebound back in the coming quarters. Indoco’s domestic business has performed better than industry and our strategies have paved well for growth in the coming quarters as well. On the International Business front, the growth during the quarter was marginal due to slowdown in emerging market tender business but we envisage to close the year with better numbers."

HIGHLIGHTS:

For Third Quarter ended December 2012 of FY 2012-13

Net Revenues at Rs.1502.6 million
EBIDTA at Rs.225.0 million
Profit After Tax at Rs.73.8 million
EPS at Rs.0.80
(Face value of Rs.2/- per share after split & bonus)


For Nine Months ended December 2012 of FY 2012-13

Net Revenues at Rs.4659.5 million
EBIDTA at Rs.777.6 million
Profit After Tax at Rs.298.1 million
EPS at Rs.3.23
(Face value of Rs.2/- per share after split & bonus)


^Top
 
 
Indoco’s Revenues Grows by 13.5%
November 2, 2012

November 2, 2012, Mumbai: Indoco Remedies Limited, a pharmaceutical company with global presence, recorded a growth of 13.5% in the revenues at Rs.1645.3 million during the second quarter of FY 2012-13 as compared to Rs.1449.8 million over the same quarter last year. The un-audited results for the second quarter of the financial year 2012-13 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on November 2, 2012.

Commenting on the performance, Mr. Suresh G. Kare, Executive Chairman said, "Our domestic business is doing well with growth rates better than that of industry average for the current as well as previous quarter. On the International Business front, the projects signed with alliance partners are getting commercialized. As envisaged, the company is set to take a big leap by registering higher growth consistently."

HIGHLIGHTS:

For Second Quarter ended September 2012 of FY 2012-13

Net Revenues at Rs.1645.3 million
EBIDTA at Rs.260.4 million
Profit After Tax at Rs.120.8 million
EPS at Rs.1.31
(Face value of Rs.2/- per share after split & bonus)


^Top
 
 
Indoco’s Revenues Grow by 20.2% with improved EBIDTA margins
July 30, 2012

July, 30, 2012, Mumbai: Indoco Remedies Limited, a pharmaceutical company with global presence, recorded a growth of 20.2% in the revenues at Rs. 1511.6 million during the first quarter of FY 2012-13 as compared to Rs. 1257.4 million over the same quarter last year. The EBIDTA for the quarter was 19.3% at Rs. 292.2 million as compared to 16.3% at Rs. 205.0 million over the same quarter last year. The un-audited results for the first quarter of the financial year 2012-13 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on July 30, 2012.

Commenting on the performance, Ms. Aditi Panandikar, Managing Director said, "Indoco’s Domestic Business has gathered momentum and registered an impressive growth during the quarter. Overall, the Company is doing fairly well and we are on track to achieve our intended objectives."

Mr. Sundeep V. Bambolkar, Jt. Managing Director added, "We are looking for qualitative growth in the International Business and have taken the cost control measures across functions to further improve our margins. With our own filing of ANDAs and Dossiers in the Regulated Markets, we shall be moving up the value-chain, resulting in higher profitability."

HIGHLIGHTS:

For First Quarter ended June 2012 of FY 2012-13

Net Revenues at Rs. 1511.6 million
EBIDTA at Rs. 292.2 million
Profit After Tax at Rs. 103.5 million
EPS at Rs. 1.12 (Face value of Rs.2/- per share after split & bonus)


^Top
 
 
Indoco’s Revenues Grow by 22.4% Q-o-Q and by 16.9% Y-o-Y
May 28, 2012

May, 28, 2012, Mumbai: During the fourth quarter of FY 2011-12, Indoco Remedies Limited, a pharmaceutical company with global presence, recorded a growth of 22.4% in the revenues at Rs. 1476.6 million as compared to Rs. 1206.3 million over the same quarter last year. For the full year, the company registered a growth of 16.9% at Rs. 5601.3 million as compared to Rs. 4790.6 million over last year. The EBIDTA for the quarter stood at Rs. 246.0 million as compared to Rs. 200.4 million over the same quarter last year and the EBIDTA for the year stood at Rs. 953.9 million as compared to Rs. 770.6 million last year. The un-audited results for the fourth quarter of the financial year 2011-12 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on May 28, 2012.

Commenting on the performance, Ms. Aditi Panandikar, Managing Director said, “Indoco has done fairly well inspite of a slowdown in the economy. However, we have a highly optimistic view of the future and are all set to take a big leap both in Domestic as well as International Business.”

Mr. Sundeep V. Bambolkar, Jt. Managing Director added, “With the required infrastructure in place, well chosen product pipeline and alliances with the top generic companies of the world, it is time for Indoco to embark on the next horizon of the success curve.”

HIGHLIGHTS:

For Fourth Quarter ended March 2012 of FY 2011-12:

Net Revenues at Rs. 1476.6 million
EBIDTA at Rs. 246.0 million
Profit After Tax at Rs. 125.3 million
EPS at Rs. 10.20 (Face value of Rs.10/- per share)
EPS at Rs. 1.36 (Face value of Rs.2/- per share after split & bonus)



For the Year ended March 2012 of FY 2011-12:

Net Revenues at Rs. 5601.3 million
EBIDTA at Rs. 953.9 million
Profit After Tax at Rs. 463.4 million
EPS at Rs. 37.72 (Face value of Rs.10/- per share)
EPS at Rs. 5.03 (Face value of Rs.2/- per share after split & bonus)



^Top
 
 
Indoco's Revenues Grow by 24 %
February 14, 2012

February, 14, 2012, Mumbai: During the third quarter of FY 2011-12, Indoco Remedies Limited, a pharmaceutical company with global presence, recorded a growth of 24% in the revenues at Rs. 1415.2 million as compared to Rs. 1143.1 million over the same quarter of previous year. The EBIDTA for the quarter stood at Rs. 162.9 million as compared to Rs. 145.0 million over the same quarter of previous year and the EBIDTA for the nine months period is at Rs. 555.7 million as compared to Rs. 544.2 million over the same period of previous year. The un-audited results for the third quarter of the financial year 2011-12 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on February 14, 2012.

Commenting on the performance, Mr. Suresh G. Kare, Chairman & Managing Director said, “The recessionary trend has affected the margins of the Industry in general. However the growth expectations for the pharma sector look bright in the domestic space as well as emerging markets. Indoco has registered an impressive growth in revenues for the third quarter in line with the Industry trend. The recent major development at Indoco is an alliance with DSM, a € 9 billion company headquartered in Europe, for marketing and distribution of some of the APIs developed & manufactured by Indoco. This step is in line with Indoco’s strategy of forging alliances and partnerships to expand its global presence. ”

HIGHLIGHTS:

For Third Quarter ended December 2011 of FY 2011-12:

Net Revenues at Rs. 1415.2 million
EBIDTA at Rs.162.9 million
Profit After Tax at Rs. 82.6 million
EPS at Rs. 6.72



For Nine Months ended December 2011 of FY 2011-12:

Net Revenues at Rs. 4118.1 million
EBIDTA at Rs. 555.7 million
Profit After Tax at Rs. 338.1 million
EPS at Rs. 27.52



^Top
 
 
Indoco's Revenues Grow by 9 %
October 20, 2011

October, 20, 2011, Mumbai: In the second quarter FY 2011-12, Indoco Remedies Limited, a global pharmaceutical company, recorded a growth of 9.4% in the net revenue at Rs. 1447.4 million as compared to Rs. 1323.4 million over the same quarter of previous year. The profit before tax for the quarter is at Rs. 146.1 million as against Rs. 169.6 million over the same quarter of previous year. The net profit after tax is at Rs. 138.1 million as against Rs. 152.6 million over the same quarter of previous year. The un-audited results for the second quarter of the financial year 2011-12 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on October 20, 2011

Commenting on the performance, Mr. Suresh G. Kare, Chairman & Managing Director said, “The economic slowdown has adversely affected business sentiments across sectors. For the Indian Pharma market to grow, it is pertinent that the economy gathers growth momentum. Indoco has performed satisfactorily under the prevailing circumstances and hopes to better its performance going forward.”

HIGHLIGHTS:

For Second Quarter ended September 2011 of FY 2011-12:

Net Revenues at Rs. 1447.4 million
Profit Before Tax at Rs. 146.1 million
Profit After Tax at Rs. 138.1 million
EPS at Rs. 11.24



^Top
 
 
Indoco's Revenues Grow by 13 %
July 28, 2011

July, 28, 2011, Mumbai: In the first quarter FY 2011-12, Indoco Remedies Limited, a global pharmaceutical company, recorded a growth of 12.7% in the net revenue at Rs. 1255.5 million as compared to Rs. 1113.8 million over the same quarter previous year. The profit before tax for the quarter is at Rs. 138.0 million as against Rs. 152.1 million over the same quarter previous year. The net profit after tax is at Rs. 117.4 million as against Rs. 148.2 million over the same quarter previous year. The un-audited results for the first quarter of the financial year 2011-12 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on July 28, 2011.

Commenting on the performance, Mr. Suresh G. Kare, Chairman & Managing Director said, “The financial performance for the first quarter is as per the expectations. Analysts have predicted that the Pharma market will be bullish in the long run and have predicted a healthy growth of over 17% for the current fiscal year. Going by the industry trends, Indoco also hopes to better its performance over the previous year.”

HIGHLIGHTS:

For First Quarter ended June 2011 of FY 2011-12:

Net Revenues at Rs. 1255.5 million up 12.7 %
Profit Before Tax at Rs. 138.0 million
Profit After Tax at Rs. 117.4 million
EPS at Rs. 9.56



^Top
 
 
Indoco’s Profit After Tax Grows by 48 %
April 27, 2011

April, 27, 2011, Mumbai: In the fourth quarter FY 2010-11, Indoco Remedies Limited, a global pharmaceutical company, recorded a growth of 47.8% in the Profit After Taxes (PAT) at Rs. 121.6 million as compared to Rs. 82.3 million over the same quarter previous year. The net revenues grew higher to Rs. 1204.4 million as against Rs. 1088.7 million over the same quarter previous year. During the year ended 31st March 2011, the net revenues grew higher by 20.1% to Rs. 4784.7 million from Rs. 3982.9 million and the Profit After Tax (PAT) grew by 21.3% to Rs. 510.5 million as compared to Rs. 420.9 million previous year. The un-audited results for the fourth quarter of the financial year 2010-11 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on April 27, 2011.

Commenting on the performance, Mr. Suresh G. Kare, Chairman & Managing Director said, “The financial performance for the quarter as well as for the year has been as per the expectations. During Q4 FY10-11, the International and API business performed very well. The domestic formulation also performed well despite the domestic formulation industry facing challenges like sluggish prescription trends etc. There is a sense of satisfaction that during the past years, all the tactical streamlining carried out has brought the desired results. Partnership alliances in the international markets with Watson and Aspen have placed Indoco on a firm-footing and the relationship with them is growing stronger. Looking ahead, Indoco aims on achieving a double digit growth on both domestic and international fronts”.

HIGHLIGHTS:

For Fourth Quarter ended March 2011 of FY 2010-11:

Net Revenue’s at Rs.1204.4 million up 10.6 %
Profit After Tax at Rs. 121.6 million up 47.8 %
EPS at Rs. 9.90 up 47.8 %


For the year ended March 2011 of FY 2010-11:

Net Revenue’s at Rs.4784.7 million up 20.1 %
Profit After Tax at Rs. 510.5 million up 21.3 %
EPS at Rs. 41.55 up 21.3 %



^Top
 
 
Indoco’s Revenues Grows By 20%
Profit Before Tax Grows By 35%

January 20, 2011

The revenues of Indoco Remedies Limited, a global pharmaceutical company, have grown by 20.4 % at Rs. 1154.9 million compared to Rs. 959.6 million, over same quarter previous year. Profit Before Tax for the quarter was Rs. 105.0 million as against Rs. 78.0 million showing a growth of 34.6% over the same quarter previous year. Profit After Tax for the quarter was Rs. 88.1 million as against Rs. 77.3 million over the same quarter last year. The third quarter un-audited results for the financial year 2010-11 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on January 20, 2011.

Commenting on the performance, Mr. Suresh G. Kare, Chairman & Managing Director said, “The performance of the Company has been quite good during the quarter and going forward, the Company will positively surpass the annual target. The growth momentum of Pharma Industry continued to be good in Q3FY11. The trend seems to be positive in the ensuing quarter as well. At Indoco, the International and API business performed very well. The domestic formulation also performed quite well. The expansion / modernization program initiated by the company at its various plants and at R&D centre are nearing completion and the same will help in catering to the diverse demands of its domestic and international markets”.

HIGHLIGHTS:

For Third Quarter ended December 2010 of FY 2010-11:

Net Revenue’s at Rs.1154.9 million up 20.4 %
Profit Before Tax at Rs. 105.0 million up 34.6 %
EPS at Rs. 7.17 up 14.0 %


For Nine Month’s Period ended December 2010 of FY 2010-11:

Net Revenue’s at Rs.3638.0 million up 24.3 %
Profit Before Tax at Rs. 426.7 million up 23.1 %
EPS at Rs. 31.65 up 14.9 %



^Top